Circulation Publishes Results From RUTHERFORD Study Which Showed AMG 145 Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia Read more about Circulation Publishes Results From RUTHERFORD Study Which Showed AMG 145 Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia
Journal of the American Medical Association Publishes AMG 145 Phase 2 GAUSS Study Showing Significant Reductions In LDL Cholesterol In Statin-Intolerant Patients Read more about Journal of the American Medical Association Publishes AMG 145 Phase 2 GAUSS Study Showing Significant Reductions In LDL Cholesterol In Statin-Intolerant Patients
Phase 3 Sensipar®/Mimpara® EVOLVE(TM) Trial Published In The New England Journal Of Medicine Read more about Phase 3 Sensipar®/Mimpara® EVOLVE(TM) Trial Published In The New England Journal Of Medicine
Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012 Read more about Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2012 Read more about Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2012
Amgen Announces Webcast of 2012 Third Quarter Financial Results Read more about Amgen Announces Webcast of 2012 Third Quarter Financial Results
Amgen Presents Several Sub-Analyses At ASBMR From The Ongoing Open-Label Extension Study Of The Pivotal Phase 3 Prolia Fracture Trial Read more about Amgen Presents Several Sub-Analyses At ASBMR From The Ongoing Open-Label Extension Study Of The Pivotal Phase 3 Prolia Fracture Trial
Amgen Appoints Cynthia Patton Senior Vice President And Chief Compliance Officer Read more about Amgen Appoints Cynthia Patton Senior Vice President And Chief Compliance Officer
Amgen Announces 2012 Fourth Quarter Dividend Read more about Amgen Announces 2012 Fourth Quarter Dividend
FDA Approves New Indication For Prolia® (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture Read more about FDA Approves New Indication For Prolia® (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture
